Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$1.82
-$0.17(-7.61%)
At close: 4:00 PM EST
$1.82
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.79 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)5.10M
Market Cap
$81.29M
Enterprise Value$84.93M
Total Cash (Recent Filing)$8.90M
Total Debt (Recent Filing)$34.70M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Feb 13, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding44,419,530
10 Day Avg. Volume3,990,467
30 Day Avg. Volume5,101,124
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00003
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue50.69
Enterprise Value/Gross Profit77.73
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$5.50Price Target Upside202.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial, with mostly positive data.
Market ExpansionOutlook has launched LYTENAVA commercially in the U.K. and Germany, and the European launch is going well and may be breakeven in 2026.
Stock ValuationMaintaining a BUY rating, but raising the 12-month price target to $10.00, based on a NPV analysis, representing significant upside from the current share price.
Bears Say
Development Pipeline RiskONS-5010 is the company's sole active development program, presenting a risk if it fails.
Financial StabilityOutlook may need additional financing to reach profitability.
Regulatory ChallengesThe FDA issued a Complete Response Letter (CRL) for the resubmitted BLA for ONS-5010, noting a lack of substantial evidence of effectiveness.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.79 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $81.29M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Feb 13, 2026 which is in 48 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Dec 19, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.2.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 44,419,530 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (202.20% Upside)
$5.50 (202.20% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.45%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$5.50
▲(202.20% Upside)
Technical Analysis
Ownership Overview
31.77% Insiders
3.29% Mutual Funds
0.48% Other Institutional Investors
61.68% Public Companies and Individual Investors